UAE Becomes Second Country to Approve Oral Wegovy for Weight Management
In a significant advancement for obesity treatment, the United Arab Emirates (UAE) has approved a new once-daily oral version of Wegovy (semaglutide) for long-term weight management. The approval was announced by the Emirates Drug Establishment (EDE), making the UAE only the second country in the world to authorize the innovative treatment.
Developed by Novo Nordisk, the oral formulation offers a convenient alternative to injectable weight-loss medications and is expected to expand access to effective obesity treatment for eligible patients.
What Is Oral Wegovy?
Wegovy contains semaglutide, a medication belonging to the GLP-1 receptor agonist class. These medicines work by mimicking a naturally occurring hormone that helps regulate appetite, food intake, and blood sugar levels.
The newly approved oral tablet is designed for:
- Long-term weight management in adults with obesity.
- Adults who are overweight and have weight-related health conditions.
- Supporting weight loss and weight maintenance when combined with a reduced-calorie diet and increased physical activity.
The oral version provides patients with a non-injectable option while delivering similar therapeutic benefits.
Clinical Studies Show Strong Weight Loss Benefits
The UAE’s approval was based on clinical studies demonstrating the effectiveness of oral Wegovy in helping patients achieve significant and sustainable weight loss.
Research showed that patients taking semaglutide alongside healthy lifestyle changes experienced:
- Meaningful weight reduction.
- Improved long-term weight maintenance.
- Better overall health outcomes.
- Enhanced management of obesity-related complications.
Experts believe the availability of an oral formulation may improve treatment adherence among patients who prefer tablets over injections.
Cardiovascular Benefits Beyond Weight Loss
One of the most notable aspects of the approval is the medication’s proven cardiovascular benefits.
According to the Emirates Drug Establishment, clinical data demonstrated that oral Wegovy can help reduce the risk of major adverse cardiovascular events among high-risk individuals, including:
- Cardiovascular death.
- Heart attacks.
- Strokes.
These findings position semaglutide as more than just a weight-loss medication, offering potential protection against some of the most serious health risks associated with obesity.
UAE Strengthens Its Position in Healthcare Innovation
The approval reflects the UAE’s commitment to adopting cutting-edge healthcare technologies and providing patients with early access to innovative treatments.
The country had previously approved the injectable version of Wegovy, which has gained global attention for its effectiveness in managing obesity and reducing cardiovascular risks.
By approving the oral formulation, the UAE continues to strengthen its reputation as a leader in healthcare innovation and pharmaceutical regulation.
EDE Highlights Importance of Addressing Obesity
Dr. Fatma Al Kaabi, Director General of the Emirates Drug Establishment, emphasized the importance of tackling obesity and overweight conditions, which are major contributors to chronic diseases worldwide.
She stated that the approval aligns with the establishment’s mission to:
- Support innovative pharmaceutical solutions.
- Improve access to advanced therapies.
- Strengthen public health outcomes.
- Ensure treatments meet internationally recognized scientific standards.
The move also supports national efforts to raise awareness about early obesity management and the prevention of related health complications.
Why This Approval Matters
Obesity has become one of the most pressing global health challenges, increasing the risk of:
- Type 2 diabetes.
- Heart disease.
- Stroke.
- High blood pressure.
- Certain cancers.
- Sleep disorders.
Access to effective medications such as oral Wegovy can help patients manage their weight more successfully while reducing long-term health risks.
The convenience of a once-daily pill may encourage more patients to seek treatment and remain committed to their weight-management plans.
Future of Weight Loss Treatment
The approval of oral Wegovy signals a growing trend toward more accessible and patient-friendly obesity treatments. As healthcare systems continue to recognize obesity as a chronic medical condition requiring long-term management, innovative therapies like semaglutide are expected to play a critical role.
With its proven effectiveness in both weight management and cardiovascular risk reduction, oral Wegovy may become a valuable option for millions of patients seeking safer and more convenient ways to improve their health.
Conclusion
The UAE’s approval of the oral version of Wegovy marks a major milestone in obesity care and preventive medicine. As the second country globally to authorize the treatment, the UAE reinforces its commitment to healthcare innovation and patient access to advanced therapies.
By combining effective weight loss support with cardiovascular protection, oral semaglutide offers a promising new option for individuals living with obesity or overweight-related health conditions. Its approval represents another important step toward addressing one of the world’s most significant public health challenges.
Recommended Products
